Senate passes bill allowing Medicaid coverage pathway for FDA‑approved obesity medications

Senator Boudreau presented Senate Bill 433, described in the transcript as creating a framework to allow Medicaid coverage of medically necessary, FDA‑approved obesity medications while preserving the Louisiana Department of Health's authority to set coverage criteria, prior authorization rules and align the benefit with available funding and federal requirements.

"What the bill does is it creates a pathway for coverage of FDA approved obesity medications when medically necessary and prescribed by a licensed provider," Senator Boudreau said, stressing that the structure of the benefit would be set by the Department of Health and is not automatic or open‑ended. He said the department retains authority to control utilization and cost. After the sponsor moved final passage, the Senate recorded a 31–0 vote in favor.

Why it matters: The bill establishes a statutory pathway for Medicaid coverage of obesity medications for eligible beneficiaries while leaving benefit design and cost controls to the department. The sponsor cited Louisiana's higher obesity rates ("between 39 and 40 percent") as part of the policy rationale. The transcript records sponsor remarks and the recorded vote but does not include detailed coverage criteria or fiscal estimates.

The Senate advanced the bill and laid a motion to reconsider on the table.